- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07561320
Mechanochemical Ablation Versus Ultrasound-Guided Foam Sclerotherapy of the Great Saphenous Vein
Mechanochemical Ablation Versus Ultrasound-Guided Foam Sclerotherapy of the Great Saphenous Vein: Randomized Clinical Trial
This study compares two minimally invasive treatments for varicose veins in the legs, specifically the great saphenous vein.
Varicose veins can cause symptoms such as leg pain, swelling, and skin changes. One commonly used treatment is foam sclerotherapy, where a special foam is injected into the vein to close it. This method is simple and allows patients to return quickly to their daily activities, but sometimes the vein can reopen, requiring additional treatments.
Another option is mechanochemical ablation, which combines a small device with a medication to close the vein. This method also allows for quick recovery and may have a lower chance of the vein reopening.
In this study, 50 patients with varicose veins will be randomly assigned to receive one of these two treatments. Doctors will follow patients over time to evaluate:
How well the treated vein stays closed Improvement in quality of life Pain during the procedure Possible complications All procedures are performed with local anesthesia, and additional small varicose veins are treated at the same time.
연구 개요
상태
상세 설명
Introduction:
Ultrasound-guided foam sclerotherapy is a widely used method for the treatment of lower limb varicose veins. Its main advantages include applicability in patients at high surgical risk and immediate or early return to daily activities. However, it requires a higher number of reinterventions compared to other techniques due to increased rates of venous recanalization, particularly in larger-caliber veins. In contrast, mechanochemical ablation shares these advantages and is associated with lower recanalization rates.
Objective:
To compare ultrasound-guided foam sclerotherapy of the great saphenous vein (GSV) with mechanochemical ablation using the Flebogrif® catheter in the treatment of chronic venous insufficiency (CVI) associated with GSV disease. The primary endpoints will be quality of life assessment and GSV occlusion rate, as determined by lower limb venous color Doppler ultrasonography over the proposed follow-up period. Secondary endpoints include the incidence of treatment-related complications and pain level during the procedure.
Patients and Methods:
A total of 50 patients with primary varicose veins will be selected. Inclusion criteria include lower limb pain, edema, or skin changes such as hyperpigmentation, eczema, and lipodermatosclerosis (CEAP classification C2-C4, EpAsPr), as well as GSV insufficiency with a diameter between 6 and 12 mm measured at the mid-thigh using color Doppler ultrasonography. Clinical evaluations and ultrasound examinations will be conducted at the venous disease outpatient clinic, and procedures will be performed in the minor surgery operating room of the University of São Paulo Hospital.
This will be a prospective randomized study, with patients allocated into two groups according to the treatment technique.
Group 1: Percutaneous puncture and ultrasound-guided injection of sclerosant foam through a short 18G catheter.
Group 2: Use of the Flebogrif® catheter, positioned under ultrasound guidance 2 cm from the saphenofemoral junction, followed by catheter withdrawal combined with sclerosant foam injection.
In both groups, 20 mL of 0.9% saline solution will be infused prior to polidocanol administration. The GSV puncture site will depend on the extent of insufficiency (segmental or total), being performed at the knee or medial malleolar region, respectively, after local anesthesia with 2% lidocaine without vasoconstrictor and without infiltration along the venous course.
For knee-level puncture, a tourniquet will be applied distal to the access site and maintained for 5 minutes after foam injection to prevent dispersion into healthy venous segments.
In all patients, varicose tributaries will be treated immediately after the GSV procedure using 1% polidocanol sclerotherapy.
Expected Results:
Mechanochemical ablation is expected to demonstrate a higher target vein occlusion rate with lower recanalization rates, without increased procedural pain and with at least a comparable complication rate to ultrasound-guided foam sclerotherapy. This study aims to contribute to the refinement of treatment strategies, seeking greater efficacy with monotherapy.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Antonio Zerati, PhD
- 전화번호: +5511996354925
- 이메일: a.zerati@fm.usp.br
연구 장소
-
-
São Paulo
-
São Paulo, São Paulo, 브라질
- 모병
- Hospital da Clínicas da FMUSP
-
연락하다:
- Victor Minari Campos, MD
- 전화번호: +5511997596010
- 이메일: victorminaricampos@gmail.com
-
수석 연구원:
- Antonio Zerati, PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- CEAP Classification C2, 3 or 4
- Insufficient great saphenous vein measuring 6-12 mm in the mid-thigh on Doppler ultrasound.
Exclusion Criteria:
- Allergy to sclerosing substances
- Deep venous thrombosis, stroke, or pulmonary embolism
- Local or generalized infection at the sclerotherapy site
- Prolonged immobilization
- Asymptomatic patent foramen ovale
- Pregnancy Occlusive peripheral arterial disease
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Great saphenous vein insufficiency (1)
25 limbs with great saphenous vein insufficiency
|
Mechanical-chemical ablation is a technique for treating varicose veins that combines mechanical damage to the venous endothelium with chemical damage using polidocanol foam.
Polidocanol foam is a drug infused into varicose veins, causing chemical damage to the endothelium.
|
|
실험적: Great saphenous vein insufficiency (2)
25 limbs with great saphenous vein insufficiency
|
Mechanical-chemical ablation is a technique for treating varicose veins that combines mechanical damage to the venous endothelium with chemical damage using polidocanol foam.
Polidocanol foam is a drug infused into varicose veins, causing chemical damage to the endothelium.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Quality Of Life Score: Brazilian Version Adapted from the Aberdeen Varicose Veins Questionnaire
기간: From enrollment to the end of treatment at 365 days after procedure
|
Brazilian Version Adapted from the Aberdeen Varicose Veins Questionnaire will be used.
Score from 0 to 100, where 0 is the best and 100 is the worst quality of life related to varicose veins.
|
From enrollment to the end of treatment at 365 days after procedure
|
|
Disease Severity Score: Venous Clinical Severity Score (VCSS)
기간: From enrollment to the end of treatment at 365 days after procedure
|
Venous Clinical Severity Score (VCSS) will be used.
Score from 0 to 30, where 0 means asymptomatic patient and 30 means more symptomatic patient as possible.
|
From enrollment to the end of treatment at 365 days after procedure
|
|
Ultrasound Assessment: Classification of the Second European Consensus Meeting on Foam Sclerotherapy Held in Tegernsee, Germany in 2006
기간: From enrollment to the end of treatment at 365 days after procedure
|
Classification of the Second European Consensus Meeting on Foam Sclerotherapy Held in Tegernsee, Germany in 2006, will be used.
Classification where 0 means reflux greater than 1 second, 1 means reflux less than 1 second, and 2 means no reflux.
|
From enrollment to the end of treatment at 365 days after procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment complications
기간: One to 365 after procedure
|
Deep vein thrombosis, thrombophlebitis, visual disturbances, skin irritation and skin hyperpigmentation.
|
One to 365 after procedure
|
|
Pain Level During Procedure: Visual Analog Pain Scale
기간: Pain level during the procedure
|
Visual Analog Pain Scale will be used.
Scale where 0 means no pain and 10 means maximum pain during procedure.
|
Pain level during the procedure
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Nicolaides AN, Allegra C, Bergan J, Bradbury A, Cairols M, Carpentier P, Comerota A, Delis C, Eklof B, Fassiadis N, Georgiou N, Geroulakos G, Hoffmann U, Jantet G, Jawien A, Kakkos S, Kalodiki E, Labropoulos N, Neglen P, Pappas P, Partsch H, Perrin M, Rabe E, Ramelet AA, Vayssaira M, Ioannidou E, Taft A. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol. 2008 Feb;27(1):1-59. No abstract available.
- Epstein D, Onida S, Bootun R, Ortega-Ortega M, Davies AH. Cost-Effectiveness of Current and Emerging Treatments of Varicose Veins. Value Health. 2018 Aug;21(8):911-920. doi: 10.1016/j.jval.2018.01.012. Epub 2018 Mar 15.
- Petrone A, Peluso A, Ammollo RP, Turchino D, Del Guercio L, Andreucci M, Serra R, Bracale UM. Selective crossectomy combined with mechanochemical ablation in the treatment of great saphenous vein insufficiency: Early results of a single center experience. Phlebology. 2022 Aug;37(7):522-528. doi: 10.1177/02683555221092194. Epub 2022 Apr 25.
- Whing J, Nandhra S, Nesbitt C, Stansby G. Interventions for great saphenous vein incompetence. Cochrane Database Syst Rev. 2021 Aug 11;8(8):CD005624. doi: 10.1002/14651858.CD005624.pub4.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 83198024.0.0000.0068
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .